^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Source:
Title:

013 | KT-413, A NOVEL IRAKIMID DEGRADER OF IRAK4 AND IMID SUBSTRATES, HAS A DIFFERENTIATED MOA THAT LEADS TO SINGLE-AGENT AND COMBINATION REGRESSIONS IN MYD88MT LYMPHOMA MODELS

Published date:
06/09/2021
Excerpt:
KT-413 also showed strongly additive activity in combination with rituximab or BTK inhibitors in MYD88MT OCI-Ly10 xenografts in vivo, suggesting the potential for therapeutically relevant drug combinations in MYD88MT DLBCL.